The INTEGRATE phase 3 (P3) trial in advanced gastric and esophagogastric junction cancer involved pooling overall survival (OS) data with its preceding phase 2 (P2) trial, raising concerns about misalignment due to treatment switching in P2 or the Winner's curse.
We evaluated P2 results, adjusted for these opposing effects, against P3 according to the prespecified statistical analysis plan.
